Literature DB >> 15772931

Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies.

Jaeseok Yang1, Kwon Wook Joo, Yon Su Kim, Curie Ahn, Jin Suk Han, Suhnggwon Kim, Jung Sang Lee.   

Abstract

We report on two Korean patients who developed pure red-cell aplasia (PRCA) due to anti-erythropoietin (EPO) antibodies. The first patient became refractory to EPO treatment after a good response for an initial 26 months. Anti-EPO antibodies were detected by enzyme linked immunosorbent assay (ELISA) and by radioimmunoprecipitation (RIPA), and these were found to inhibit erythroid colony formation by in vitro bioassay. In the second patient, the anemia became aggravated, accompanied by thrombocytopenia and wheals appeared at the EPO injection site 3 months after the initiation of subcutaneous EPO treatment. Anti-EPO antibodies were detected by ELISA, and the patient showed a partial response to the second corticosteroid treatment course. Our cases demonstrate that PRCA due to anti-EPO antibodies becomes an important issue in Asians as well as in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772931

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  4 in total

Review 1.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

2.  Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.

Authors:  Hajeong Lee; Jaeseok Yang; Hyosang Kim; Ju Won Kwon; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Curie Ahn; Jin Suk Han; Suhnggwon Kim
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

Review 3.  Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 4.  Biosimilar drugs: Current status.

Authors:  Rajiv Kumar; Jagjit Singh
Journal:  Int J Appl Basic Med Res       Date:  2014-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.